Member info
Pr Julian Garcia Feijoo
Representative
Spain
Working Group(s): Pediatric Ophthalmology Rare Diseases (WG3), Low Vision Daily Life and Patients Groups (TWG5), Genetic Diagnostics (TWG6), Research (TWG8), National Integration (TWG9), CPMS & Digital Medecine (TWG10)
Team
Dr Carmen Mendez Hernandez
Spain
CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8)
Dr Jose Manuel Benitez del Castillo
Spain
Anterior Segment Rare Eye Diseases (WG4), CPMS & Digital Medecine (TWG10), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Research (TWG8)
Dr Juan Donate López
Spain
CPMS & Digital Medecine (TWG10), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Dr Rosario Gomez de Liaño
Spain
CPMS & Digital Medecine (TWG10), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8)
Dr Enrique Santos Bueso
Spain
CPMS & Digital Medecine (TWG10), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Research (TWG8)
Dr Alicia Valverde Megias
Spain
CPMS & Digital Medecine (TWG10), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)
HCP Center
The Hospital Clínico San Carlos is a Health Centre that since its constitution in 1787 has among its objectives the improvement of care, teaching...
contact
Hospital Clinico San Carlos, Madrid, Spain
Calle del Prof Martín Lagos, s/n
28040 Madrid
Spain
Clinical trials
NCT04270747 Completed
A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects With Neovascular Age-related Macular Degeneration
Interventional
NCT04276558 Recruiting, Active
Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients
Interventional
NCT01756456 Completed
Evaluation of safety and efficacy of r-hNGF in patients with stage 2 and 3 Neurotrophic Keratitis (REPARO).
Interventional